H.C. Wainwright Maintains Buy on SpringWorks Therapeutics, Raises Price Target to $40

H.C. Wainwright maintains SpringWorks Therapeutics (NASDAQ:SWTX) with a Buy and raises the price target from $34 to $40.

Benzinga · 01/21/2020 12:53

H.C. Wainwright maintains SpringWorks Therapeutics (NASDAQ:SWTX) with a Buy and raises the price target from $34 to $40.